A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
← catalyst calendarNCT03941379 · readout ≤ 865 d
Sponsored by Aura Biosciences (industry) · AURA — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
63actual
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-03-27 | actual | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Choroidal Melanoma
- Indeterminate Lesions of Eye
Primary outcome
what the primary-completion date above is the date OFIncidence of Adverse Events and Serious Adverse Events that are related to IL/CM treatment with bel-sar.
measured 5 years
Permalink · AURA's whole pipeline · Catalyst calendar · Every registered study · What changed